PL1603577T3 - Związki do leczenia bólu - Google Patents

Związki do leczenia bólu

Info

Publication number: PL1603577T3
Authority: PL; Poland
Prior art keywords: compounds; treatment; pain; formula; methoxyadenosine
Prior art date: 2003-03-07

Application number

PL04717707T

Other languages

English (en)

Inventor

Peter Richardson

Kevin Lee

Lisa Lione

Original Assignee

Cambridge Biotechnology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-07

Filing date

2004-03-05

Publication date

2009-01-30

2004-03-05 Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd

2009-01-30 Publication of PL1603577T3 publication Critical patent/PL1603577T3/pl

Links

150000001875 compounds Chemical class 0.000 title abstract 3
AJACDNCVEGIBNA-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O AJACDNCVEGIBNA-KQYNXXCUSA-N 0.000 abstract 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
AJACDNCVEGIBNA-UHFFFAOYSA-N 2-Methoxyadenosine Natural products C12=NC(OC)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O AJACDNCVEGIBNA-UHFFFAOYSA-N 0.000 abstract 1
150000003838 adenosines Chemical class 0.000 abstract 1
229940035676 analgesics Drugs 0.000 abstract 1
239000000730 antalgic agent Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Virology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)

PL04717707T 2003-03-07 2004-03-05 Związki do leczenia bólu PL1603577T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0305149.7A GB0305149D0 (en)	2003-03-07	2003-03-07	Compounds for the treatment of pain
PCT/GB2004/000935 WO2004078183A1 (en)	2003-03-07	2004-03-05	Compounds for the treatment of pain
EP04717707A EP1603577B1 (en)	2003-03-07	2004-03-05	Compounds for the treatment of pain

Publications (1)

Publication Number	Publication Date
PL1603577T3 true PL1603577T3 (pl)	2009-01-30

Family

ID=9954247

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04717707T PL1603577T3 (pl)	2003-03-07	2004-03-05	Związki do leczenia bólu

Country Status (19)

Country	Link
US (1)	US7759321B2 (pl)
EP (1)	EP1603577B1 (pl)
JP (1)	JP2006519823A (pl)
KR (1)	KR20050115273A (pl)
CN (1)	CN100579533C (pl)
AT (1)	ATE401087T1 (pl)
AU (1)	AU2004216889B2 (pl)
CA (1)	CA2514098A1 (pl)
CY (1)	CY1108416T1 (pl)
DE (1)	DE602004015085D1 (pl)
DK (1)	DK1603577T3 (pl)
ES (1)	ES2310288T3 (pl)
GB (1)	GB0305149D0 (pl)
NO (1)	NO20054476L (pl)
NZ (1)	NZ541521A (pl)
PL (1)	PL1603577T3 (pl)
PT (1)	PT1603577E (pl)
SI (1)	SI1603577T1 (pl)
WO (1)	WO2004078183A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0228723D0 (en)	2002-12-09	2003-01-15	Cambridge Biotechnology Ltd	Treatment of pain
GB0305153D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Identification of therapeutic compounds
GB0305150D0 (en) *	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Use of therapeutic compounds
KR20070004792A (ko) *	2004-03-05	2007-01-09	캠브리지 바이오테크놀로지 리미티드	아데노신 수용체 작용제
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US8512984B2 (en)	2004-12-01	2013-08-20	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
US8603779B2 (en)	2004-12-01	2013-12-10	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
US8778634B2 (en)	2004-12-01	2014-07-15	Syntaxin, Ltd.	Non-cytotoxic protein conjugates
US8399400B2 (en) *	2004-12-01	2013-03-19	Syntaxin, Ltd.	Fusion proteins
GB0426394D0 (en) *	2004-12-01	2005-01-05	Health Prot Agency	Fusion proteins
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
CN1947717B (zh) *	2005-10-14	2012-09-26	卓敏	选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
GB0610867D0 (en) *	2006-06-01	2006-07-12	Syntaxin Ltd	Treatment of pain
US7906518B2 (en)	2006-06-27	2011-03-15	Cbt Development Limited	Therapeutic compounds
NZ573308A (en) *	2006-06-27	2012-02-24	Biovitrum Ab Publ	Adenosine derivatives for the treatment of pain
CN101479268B (zh)	2006-06-27	2012-08-08	Cbt发展有限公司	2-0’-甲基腺苷衍生物及其用作制备腺苷受体的激动剂或拮抗剂的应用
US20140056870A1 (en)	2012-08-27	2014-02-27	Allergan, Inc.	Fusion proteins
CN103342727A (zh) *	2013-07-01	2013-10-09	淮海工学院	一种2-甲氧基腺苷的合成方法
JP6440240B2 (ja) *	2014-02-19	2018-12-19	国立大学法人富山大学	末梢神経障害誘発感覚異常を改善する外用剤
US12336977B2 (en) *	2019-07-31	2025-06-24	Sea4Us—Biotecnologia E Recursos Marinhos, Lda.	Nitenin analogue compounds and their use in the treatment of chronic and acute pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE792155A (fr) *	1971-12-01	1973-05-30	Takeda Chemical Industries Ltd	Nouveaux derives de l'adenosine et leur procede de production
JPS4861498A (pl)	1971-12-01	1973-08-28
DE2359536C2 (de)	1972-12-08	1984-08-02	Takeda Chemical Industries, Ltd., Osaka	2,6-Diaminonebularinderivate
JPS5461194A (en)	1977-10-21	1979-05-17	Takeda Chem Ind Ltd	Preparation of n22substituted 2*66diaminonebularin
JPS5461195A (en)	1977-10-21	1979-05-17	Takeda Chem Ind Ltd	N2-substituted phenyl-2,6-diaminonebularin
US4705758A (en)	1984-06-19	1987-11-10	Warner-Lambert Company	Adenosine receptor assay and kit
US5679650A (en) *	1993-11-24	1997-10-21	Fukunaga; Atsuo F.	Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5677290A (en) *	1990-05-10	1997-10-14	Fukunaga; Atsuo F.	Therapeutic use of adenosine compounds as surgical anesthetics
US5683989A (en) *	1993-12-17	1997-11-04	Novo Nordisk A/S	Treatment of ischemias by administration of 2,N6 -substituted adenosines
PL316985A1 (en) *	1994-05-10	1997-03-03	Sandoz Ltd	Derivatives of adenosine
US5877180A (en)	1994-07-11	1999-03-02	University Of Virginia Patent Foundation	Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it)	1995-06-02	1997-08-05	Schering Plough S P A	Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
JP2002500188A (ja)	1998-01-08	2002-01-08	ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション	Ａ２ａアデノシンレセプター作動因子
GB0228723D0 (en) *	2002-12-09	2003-01-15	Cambridge Biotechnology Ltd	Treatment of pain
GB0305153D0 (en)	2003-03-07	2003-04-09	Cambridge Biotechnology Ltd	Identification of therapeutic compounds

2003
- 2003-03-07 GB GBGB0305149.7A patent/GB0305149D0/en not_active Ceased
2004
- 2004-03-05 ES ES04717707T patent/ES2310288T3/es not_active Expired - Lifetime
- 2004-03-05 KR KR1020057016699A patent/KR20050115273A/ko not_active Ceased
- 2004-03-05 EP EP04717707A patent/EP1603577B1/en not_active Expired - Lifetime
- 2004-03-05 PT PT04717707T patent/PT1603577E/pt unknown
- 2004-03-05 DE DE602004015085T patent/DE602004015085D1/de not_active Expired - Lifetime
- 2004-03-05 PL PL04717707T patent/PL1603577T3/pl unknown
- 2004-03-05 CA CA002514098A patent/CA2514098A1/en not_active Abandoned
- 2004-03-05 WO PCT/GB2004/000935 patent/WO2004078183A1/en not_active Ceased
- 2004-03-05 AT AT04717707T patent/ATE401087T1/de not_active IP Right Cessation
- 2004-03-05 SI SI200430876T patent/SI1603577T1/sl unknown
- 2004-03-05 JP JP2006505920A patent/JP2006519823A/ja active Pending
- 2004-03-05 NZ NZ541521A patent/NZ541521A/en unknown
- 2004-03-05 AU AU2004216889A patent/AU2004216889B2/en not_active Ceased
- 2004-03-05 CN CN200480004454A patent/CN100579533C/zh not_active Expired - Fee Related
- 2004-03-05 US US10/547,455 patent/US7759321B2/en not_active Expired - Fee Related
- 2004-03-05 DK DK04717707T patent/DK1603577T3/da active
2005
- 2005-09-27 NO NO20054476A patent/NO20054476L/no not_active Application Discontinuation
2008
- 2008-10-15 CY CY20081101141T patent/CY1108416T1/el unknown

Also Published As

Publication number	Publication date
NO20054476D0 (no)	2005-09-27
CY1108416T1 (el)	2013-09-04
CN1750835A (zh)	2006-03-22
CN100579533C (zh)	2010-01-13
US7759321B2 (en)	2010-07-20
NO20054476L (no)	2005-11-24
AU2004216889A1 (en)	2004-09-16
ES2310288T3 (es)	2009-01-01
WO2004078183A1 (en)	2004-09-16
KR20050115273A (ko)	2005-12-07
JP2006519823A (ja)	2006-08-31
NZ541521A (en)	2008-09-26
DK1603577T3 (da)	2008-11-17
US20070066559A1 (en)	2007-03-22
HK1087629A1 (zh)	2006-10-20
ATE401087T1 (de)	2008-08-15
GB0305149D0 (en)	2003-04-09
DE602004015085D1 (de)	2008-08-28
AU2004216889B2 (en)	2009-06-11
PT1603577E (pt)	2008-10-23
EP1603577B1 (en)	2008-07-16
EP1603577A1 (en)	2005-12-14
SI1603577T1 (sl)	2008-12-31
CA2514098A1 (en)	2004-09-16

Publication	Publication Date	Title
GB0305149D0 (en)	2003-04-09	Compounds for the treatment of pain
GB2396108B (en)	2005-08-03	Treatment of pain
PT1365762E (pt)	2008-11-27	Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico
EP1343488A4 (en)	2005-05-04	TREATMENT OF SIDE EFFECTS OF STATIN
EG25822A (en)	2012-08-23	Quinolinyl-pyrrolopyrazoles
TW200806299A (en)	2008-02-01	Treatment of pain
SG159388A1 (en)	2010-03-30	Antibacterial agents
WO2008033468A3 (en)	2008-08-14	Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
TW200509949A (en)	2005-03-16	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2003024391A3 (en)	2003-05-30	Treatment and prevention of mucositis in cancer patients
WO2004110380A3 (en)	2005-03-10	Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
TW200639159A (en)	2006-11-16	Treatment of pain
EP1627635A3 (en)	2006-03-29	Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
WO2003022280A3 (en)	2003-05-22	3-glyoxlylamideindoles for treating cancer
GB0215526D0 (en)	2002-08-14	Anticancer compounds
WO2005082375A3 (en)	2005-10-13	Treatment of interstitial cystitis with vitamin d compounds
GB2426517A (en)	2006-11-29	Methods and agents for inhibiting dynamin-dependent endocytosis
MY187188A (en)	2021-09-09	Derivatives of di(phenylpropanoid) glycerol for the treatment of cancer
TW200508196A (en)	2005-03-01	Hydroxamic acids useful in the treatment of hyper-proliferative disorders
WO2008060381A3 (en)	2008-11-27	Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
WO2007047893A3 (en)	2007-06-21	Use of dasatinib for the treatment of bone metastasis
TW200730177A (en)	2007-08-16	4 anilino-3-quinolinecarbonitriles for the treatment of cancer
MXPA05006378A (es)	2006-02-08	Compuestos esteroides con actividad anti-tumoral.
AU2002211217A1 (en)	2002-04-29	Method of treating stroke
WO2003090737A3 (en)	2004-04-01	Methods and compositions for treatment of cancer pain